Figure 5: Cost effectiveness. | Nature Communications

Figure 5: Cost effectiveness.

From: Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis

Figure 5

(a) Total cases averted and total difference in costs of treatment in USD over 5 years in 492 administrative areas of Africa, comparing use of DHA–PQP with AL. (b) Incremental cost-effectiveness ratios: cost per case averted by introducing DHA–PQP as the first-line treatment instead of AL, averaged over 5 years by first administrative unit. Blue scale=areas where DHA–PQP has a positive impact on averting cases but higher overall cost than AL, red=AL dominates (averts more cases with lower costs than DHA–PQP), yellow=DHA–PQP dominates. Grey areas indicate no P. falciparum or P. falciparum slide prevalence <1% or no data.

Back to article page